JAK kinase inhibitors (JAKis) are a new class of orally targeted drugs for the treatment of RA that may prevent RA attacks in patients with undifferentiated arthritis by inhibiting the STAT4 signalling pathway (148). The gene discussed is STAT4; the disease is rheumatoid arthritis.